Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2

Status

Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 6Dermatologic 4Thoracic 3Head & Neck 3Genitourinary 3Breast 3Sarcoma 2Lymphoid 2Gynecologic 2Other hematologic neoplasm 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Breast Neoplasms 1215Triple Negative Breast Neoplasms 283Ovarian Neoplasms 262Carcinoma, Non-Small-Cell Lung 248Colorectal Neoplasms 189Pancreatic Neoplasms 168Stomach Neoplasms 164Neoplasm Metastasis 156Neoplasms 155Lung Neoplasms 144Prostatic Neoplasms 143Melanoma 132Carcinoma, Renal Cell 103Squamous Cell Carcinoma of Head and Neck 102Endometrial Neoplasms 99Head and Neck Neoplasms 88Colonic Neoplasms 82Urinary Bladder Neoplasms 79Uterine Cervical Neoplasms 77Esophageal Neoplasms 76Sarcoma 71Breast Neoplasms, Male 68Small Cell Lung Carcinoma 66Carcinoma, Hepatocellular 60Carcinoma, Ovarian Epithelial 58Kidney Neoplasms 47Carcinoma, Transitional Cell 41Rectal Neoplasms 35Fallopian Tube Neoplasms 34Liver Neoplasms 32

Interventions

pembrolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Adenoid Cystic × Breast × Clear all
NCT05377996 2026-04-14

A Study of XMT-1660 in Participants With Solid Tumors

Mersana Therapeutics

Phase 1 Recruiting
319 enrolled
BreastGynecologic

Breast Neoplasms, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05194072 2026-01-09

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Seagen Inc.

Phase 1 Terminated
250 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Cogent Biosciences, Inc.

Phase 1 Terminated
6 enrolled
BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡